.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Research confirms that mastitis breast cancer risk warrants significant attention in clinical oncology today. While chronic inflammation generally predisposes individuals to various malignancies, the specific link between mammary gland inflammation and breast cancer (BC) remained debated for years. However, a comprehensive meta-analysis now provides much-needed clarity. Specifically, investigators used R Studio software version 4.4.2 to perform a rigorous random-effects meta-analysis. Consequently, the results demonstrate a clear and statistically significant correlation between a history of mastitis and subsequent cancer development.
In India, breast cancer accounts for nearly 2.4 million new cases annually, with many patients presenting at advanced stages. Furthermore, this meta-analysis found that women with a history of mastitis have an odds ratio (OR) of 1.70. This statistic suggests a 70% higher likelihood of developing BC compared to those without prior inflammation. Additionally, the study reported a hazard ratio (HR) of 1.34. Therefore, medical professionals must incorporate mastitis history into their routine risk assessment protocols. Moreover, focusing on early detection is crucial since many Indian women lack access to structured screening programs. Consequently, identifying high-risk individuals allows for earlier intervention and significantly better survival outcomes.
Chronic inflammation can cause DNA damage and create a tumor-friendly microenvironment. Thus, it raises the mastitis breast cancer risk by facilitating neoplastic progression in the breast tissue.
Yes, several studies suggest that non-puerperal mastitis carries a more potent and immediate association with malignancy. Nevertheless, any history of significant breast inflammation requires careful long-term clinical follow-up.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
de Figueiredo Azevedo AC et al. Mastitis as a risk factor for breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2026 Apr 12. doi: 10.1007/s12094-026-04303-x. PMID: 41966678.
Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
Chen CH, et al. Risk of Breast Cancer in Women with Mastitis: A Retrospective Population-Based Cohort Study. BMC Cancer. 2020;20(1):1-10.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent meta-analysis confirms that women with a history of mastitis face a significantly higher risk of breast cancer, with an odds ratio of 1.70....
6 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
